Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Other Accumulated Expenses (2016 - 2025)

Purple Biotech has reported Other Accumulated Expenses over the past 7 years, most recently at $4.7 million for Q4 2022.

  • Quarterly Other Accumulated Expenses rose 83.55% to $4.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2022, up 83.55% year-over-year, with the annual reading at $4.7 million for FY2022, 83.55% up from the prior year.
  • Other Accumulated Expenses was $4.7 million for Q4 2022 at Purple Biotech, up from $3.0 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $5.3 million in Q1 2022 and troughed at $1.1 million in Q3 2021.
  • The 5-year median for Other Accumulated Expenses is $2.1 million (2018), against an average of $2.7 million.
  • Year-over-year, Other Accumulated Expenses tumbled 35.66% in 2021 and then skyrocketed 223.72% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.1 million in 2018, then rose by 2.48% to $2.1 million in 2019, then fell by 19.61% to $1.7 million in 2020, then soared by 52.27% to $2.6 million in 2021, then skyrocketed by 83.55% to $4.7 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Other Accumulated Expenses are $4.7 million (Q4 2022), $3.0 million (Q3 2022), and $4.0 million (Q2 2022).